Strategic Partnerships Leverage ongoing collaborations with Asieris Pharmaceuticals to co-market integrated diagnosis and treatment capabilities for bladder cancer, and explore similar cross-industry partnerships with urology-focused biotech firms to expand distribution and adoption of portable single-use cystoscopy solutions.

Expansion Footprint Target healthcare facilities in or near California and Washington where UroViu has operations, and identify international distribution opportunities leveraging Asia-based production to support cost-effective global supply and potential rapid deployment in emerging markets.

Product Portfolio Position the Always Ready single-use cystoscopy platform and recent launches such as Uro-GHD and Hystero-V as versatile entry points for hospitals seeking portable, sterile, dedicated devices; emphasize compatibility and ease of use to drive trials in ambulatory surgery centers and teaching institutions.

Market Traction Highlight revenue potential in the $1M-$10M range and pursue enterprise-level contracts with regional hospitals and outpatient networks; propose value-based offerings that emphasize reduced reprocessing costs, sterilization time savings, and patient throughput improvements.

Competitive Positioning Differentiate from larger incumbents by underscoring portability, single-use sterile design, and a broad patent portfolio; develop targeted outreach to key decision-makers in urology and gynecology to showcase total cost of ownership and clinical workflow benefits.